These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 21884469)

  • 1. Effect of various anticoagulant agents on large-volume leukocytapheresis using new Cellsorba CS-180S Filter.
    Hohtatsu K; Yamaji K; Yamada R; Oda K; Kageyama M; Kusaoi M; Onuma S; Kawamoto T; Sugimoto K; Sekiya F; Kon T; Ogasawara M; Kempe K; Tsuda H; Takasaki Y
    Ther Apher Dial; 2011 Aug; 15(4):355-9. PubMed ID: 21884469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction in bradykinin generation during leukocytapheresis using novel cellsorba(TM) CS-180S: Effects of changing the filling solution.
    Yamada R; Kusaoi M; Murayama G; Yasui M; Hishinuma R; Nemoto T; Hohtatsu K; Kageyama M; Kawamoto T; Sugimoto K; Sekiya F; Kon T; Ogasawara M; Kempe K; Yamaji K; Tsuda H; Takasaki Y
    J Clin Apher; 2014 Apr; 29(2):90-6. PubMed ID: 24023037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of anticoagulants for leukocytapheresis therapy in cases of active ulcerative colitis.
    Kanke K; Hoshino M; Tominaga K; Nakano M; Terano A; Hiraishi H
    Blood Purif; 2007; 25(4):370-6. PubMed ID: 17785966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study.
    Sawada K; Ohdo M; Ino T; Nakamura T; Numata T; Shibata H; Sakou J; Kusada M; Hibi T
    Ther Apher Dial; 2016 Apr; 20(2):197-204. PubMed ID: 26771066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced effect of high-dose leukocytapheresis using a large filter in rheumatoid arthritis.
    Eguchi K; Saito K; Kondo M; Hidaka T; Ueki Y; Tanaka Y;
    Mod Rheumatol; 2007; 17(6):481-5. PubMed ID: 18084700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of the clinical effect of large volume leukocytapheresis on methotrexate-resistant rheumatoid arthritis.
    Onuma S; Yamaji K; Kempe K; Ogasawara M; Ogawa T; Yang K; Kanai M; Tsuda H; Takasaki Y
    Ther Apher Dial; 2006 Oct; 10(5):404-11. PubMed ID: 17096694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellsorba.
    Shibata H; Kuriyama T; Yamawaki N
    Ther Apher Dial; 2003 Feb; 7(1):44-7. PubMed ID: 12921114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukocytapheresis using a leukocyte removal filter.
    Shirokaze J
    Ther Apher; 2002 Aug; 6(4):261-6. PubMed ID: 12164794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recruitment of immature neutrophils in peripheral blood following leukocytapheresis therapy for rheumatoid arthritis.
    Okawa-Takatsuji M; Nagatani K; Nakajima K; Itoh K; Kano T; Nagashio C; Takahashi Y; Aotsuka S; Mimori A
    J Clin Apher; 2007; 22(6):323-9. PubMed ID: 18095302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anticoagulation for plasmapheresis].
    Amemiya H; Sekihara H; Kobayashi T; Koiwa F; Niikura K
    Nihon Rinsho; 2004 May; 62 Suppl 5():323-7. PubMed ID: 15197938
    [No Abstract]   [Full Text] [Related]  

  • 11. Cell separating property and clinical effect of lymphocytapheresis with leukocyte removal filter.
    Akizawa T; Kinugasa E; Koshikawa S; Nishimura T; Kuroda H
    Prog Clin Biol Res; 1990; 337():23-5. PubMed ID: 2352982
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of high-throughput leukocytapheresis for rheumatoid arthritis with a reduced response to infliximab.
    Sakai Y; Sakai S; Otsuka T; Ohno D; Murasawa T; Munakata K; Mizuno K
    Ther Apher Dial; 2009 Jun; 13(3):179-85. PubMed ID: 19527463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of aprotinin with various anticoagulant agents in cardiopulmonary bypass.
    Terrell MR; Walenga JM; Koza MJ; Pifarré R
    Ann Thorac Surg; 1996 Aug; 62(2):506-11. PubMed ID: 8694614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukocytapheresis therapy by extracorporeal circulation using a leukocyte removal filter.
    Suemitsu J; Yoshida M; Yamawaki N; Yamashita Y
    Ther Apher; 1998 Feb; 2(1):31-6. PubMed ID: 10227786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of plasmapheresis or leukocytapheresis for articular and extraarticular manifestations of rheumatoid arthritis.
    Ogawa H; Matsumoto Y
    Ther Apher; 1997 Nov; 1(4):330-5. PubMed ID: 10225725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukocytapheresis in rheumatoid arthritis.
    Hidaka T; Hashiba Y; Kubo K; Kai Y; Maeda K
    Transfus Apher Sci; 2017 Oct; 56(5):698-702. PubMed ID: 28918917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukocytapheresis for ulcerative colitis: a comparative study of anticoagulant (nafamostat mesilate vs. dalteparin sodium) for reducing clinical complications.
    Ashizuka S; Nishiura R; Ishikawa N; Yamaga J; Inatsu H; Fujimoto S; Eto T
    Ther Apher Dial; 2006 Feb; 10(1):54-8. PubMed ID: 16556137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changes in coagulation, fibrinolysis and platelet functions during extracorporeal circulation].
    Kaizu K; Uriu K; Ikeda M
    Nihon Rinsho; 2004 May; 62 Suppl 5():46-9. PubMed ID: 15197886
    [No Abstract]   [Full Text] [Related]  

  • 19. Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage.
    Yang JW; Han BG; Kim BR; Lee YH; Kim YS; Yu JM; Choi SO
    Ren Fail; 2009; 31(8):668-75. PubMed ID: 19814633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of specific IgE antibodies to nafamostat mesilate as an indication of possible adverse effects of leukocytapheresis using nafamostat mesilate as anticoagulant.
    Nagase K; Fukunaga K; Ohnishi K; Kusaka T; Matoba Y; Sawada K
    Ther Apher Dial; 2004 Feb; 8(1):45-51. PubMed ID: 15128019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.